L-dopa upregulates the expression and activities of methionine adenosyl transferase and catechol-O-methyltransferase

Experimental Neurology

Volumn 171, Issue 1, 2001, Pages 127-138

  Zhao, Wan Qian ^a   Latinwo, Lekan ^a   Liu, Xiao Xiao ^a   Lee, Eun Sook ^a   Lamango, Nazarius ^a   Charlton, Clivel G ^a  

^a FLORIDA A AND M UNIVERSITY   (United States)

Author keywords

3 O methyldopa; Catechol O methyltransferase; Dopamine; L dopa; Methionine adenosyl transferase; Parkinson's disease; Potential transactivator proteins; S adenosylhomocysteine; S adenosylmethionine

Indexed keywords

3 O METHYLDOPA; CATECHOL METHYLTRANSFERASE; CATECHOL METHYLTRANSFERASE 1; CATECHOL METHYLTRANSFERASE 2; DOPAMINE; LEVODOPA; METHIONINE ADENOSYLTRANSFERASE; S ADENOSYLHOMOCYSTEINE; S ADENOSYLMETHIONINE; STRESS ACTIVATED PROTEIN KINASE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOPAMINE BRAIN LEVEL; DRUG TOLERANCE; ENZYME ACTIVITY; ENZYME INDUCTION; MALE; METHYLATION; MOLECULAR WEIGHT; MOUSE; MOUSE STRAIN; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REACTION ANALYSIS; WESTERN BLOTTING;

EID: 0034853461     PISSN: 00144886     EISSN: None     Source Type: Journal    
DOI: 10.1006/exnr.2001.7726     Document Type: Article

References (63)

1. Characterization of rat liver-specific methionine adenosyltransferase gene promoter. Role of distal upstream cis-acting elements in the regulation of the transcriptional activity
2. Oncogene jun encodes a sequence-specific trans-activator similar to AP-1
3. The complete sequence of a full length cDNA for human liver glyceraldehyde-3-phosphate dehydrogenase: Evidence for multiple mRNA species
4. Enzymatic O-methylation of epinephrine and other catechols
5. Extrapyramidal disorder
6. The effects of L-dopa on the activity of methionine adenosyltransferase: Relevance of L-dopa therapy and tolerance
7. Purification and comparison of two forms of S-adenosyl-L-methionine synthetase from rat liver
8. Activation of methionine for transmethylation. II. The methionine-activating enzyme: Studies on the mechanism of the reaction
9. Depletion of nigrostriatal and forebrain tyrosine hydroxylase by S-adenosylmethionine: A model that may explain the occurrence of depression in Parkinson's disease
10. Striatal dopamine depletion, tremors, and hypokinesia following the intracranial injection of S-adenosylmethionine
11. Tremor induced by S-adenosyl-L-methionine: Possible relation to L-dopa effects
12. Motor response complications and the function of striatal efferent systems
13. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
14. Receptor adaptations to centrally acting drugs
15. S-Adenosyl-L-methionine decreases motor activity in the rat: Similarity to Parkinson's disease-like symptoms
16. Changes in the relative amount of subunits of methionine adenosyltransferase in human lymphocytes upon stimulation with a polyclonal T cell mitogen
17. Chromosomal localization and catalytic properties of the recombinant alpha subunit of human lymphocyte methionine adenosyltransferase
18. 18F]Ro41-0960
19. Is L-dopa drug holiday useful?
20. Role of the Jun kinase pathway in the regulation of c-Jun expression and apoptosis in sympathetic neurons
21. Adverse effects of levodopa
22. Controversies in the therapy of Parkinson's disease
23. The Fos complex and Fos related antigens recognize sequence elements that contain AP-1 binding sites
24. Catechol-O-methyltransferase-deficient mice exhibit sexually dimorphic changes in catecholamine levels and behavior
25. Molecular cloning and developmental expression of a human kidney S-adenosylmethionine synthetase
26. The mechanisms of action of L-dopa in Parkinson's disease
27. Multiple molecular forms of catechol-O-methyltransferase. Evidence for two distinct forms, and their purification and physical characterization
28. Sustained levodopa therapy in parkinsonism
29. Levodopa: Pharmacology, pharmacokinetics, and pharmacodynamics
30. Effects of catechol-O-methyltransferase inhibitors and L-3, 4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum
31. Immunohistochemical study of catechol-O-methyltransferase in the human mesostriatal system
32. Levodopa-induced dopamine receptor hypersensitivity
33. Methionine adenosyltransferase: Structure and function
34. S-Adenosylmethionine synthetase from human lymphocytes. Purification and characterization
35. Consensus nomenclature for the mammalian methionine adenosyltransferase genes and gene products
36. COMT inhibition: A new treatment strategy for Parkinson's disease
37. Maturation of the head of bacteriophage T4. I. DNA packaging events
38. Receptor basis for dopaminergic supersensitivity in Parkinson's disease
39. Analysis of the clinical problems in parkinsonism and the complications of long term levodopa therapy
40. Expression of enzymatically active rat liver and human placental catechol-O-methyltransferase in Escherichia coli: Purification and partial characterization of the enzyme
41. Motoneuron apoptosis is blocked by CEP-1347 (KT 7515), a novel inhibitor of the JNK signaling pathway
42. Success and problems of long-term levodopa therapy in Parkinson's disease
43. Extending levodopa action COMT inhibition
44. Chronic L-dopa administration decreases striatal accumulation of dopamine from exogenous L-dopa in rats with intact nigrostriatal projections
45. The proline-rich transcriptional activator of CTF/NF-1 is distinct from the replication and DNA binding domain
46. Complete purification and immunochemical analysis of S-adenosylmethionine synthetase from bovine brain
47. S-Adenosyl-L-methionine synthetase from human erythrocytes: Role in the regulation of cellular S-adenosylmethionine levels
48. An introduction to the free radical hypothesis in Parkinson's disease
49. Attempts to obtain neuroprotection in Parkinson's disease
50. Neurotransmitter receptor alterations in Parkinson's disease
51. Treatment of Parkinson's disease: Problems with a progressing disease
52. Distinct cellular localization of membrane-bound and soluble forms of catechol-O-methyltransferase in brain
53. Localization of membrane-bound catechol-O-methyltransferase
54. Cloning and expression of murine S-adenosylmethionine synthetase
55. Molecular cloning and characterization of rat liver catechol-O-methyltransferase
56. The presence of catechol-O-methyltransferase activity in separately cultured cerebromicrovascular endothelial and smooth muscle cells
57. Effect of long-term L-dopa administration on the dopaminergic and cholinergic (muscarinic) receptors of striatum in 6-hydroxydopamine lesioned rats
58. Fractionation and kinetic properties of rat liver and kidney methionine adenosyltransferase isozymes
59. Crystal structure of catechol-O-methyltransferase
60. The genetic origin of responses to drugs
61. Catecholamines
62. Drug holiday and management of Parkinson disease
63. Long-term levodopa in Parkinson's disease